{"cluster": 16, "subcluster": 6, "abstract_summ": " There is no evidence that RAS inhibitors increase the risk of SARS-CoV-2 infection by facilitating greater viral entry or worsen outcomes in patients with COVID-19 . At this time, there is no clinical evidence to suggest that treatment with RAS ."}